ddn Online

The Blog of Drug Discovery News

Eisai invests $200 million in U.S. personalized medicine unit

Seems that Japanese company  Eisai has put together a biotech start-up in the United States by the name of H3 Biomedecines, intended to focus on discovering and developing next-generation cancer drugs and with an aim to generate new treatments “aimed at fulfilling the promise of personalised cancer medicine.”

H3, based in Cambridge, Mass., will be wholly owned by Eisai, which has committed to putting up $200 million in research funding. Eisai officials say the establishment of H3 is distinct from similar companies because it will have the “resources and capabilities of an established pharmaceutical company, while also encouraging and rewarding innovative and entrepreneurial spirit.”

Eisai also that its involvement will allow H3 to benefit from a longer-term view of its drug discovery activities compared to most venture-backed start-up companies.


January 31, 2011 Posted by | Corporate | | Leave a comment